An evaluation of LIT test as a marker for immunocompetence
Research type
Research Study
Full title
An evaluation of LIT test as a marker for immunocompetence in chemotherapy for cancer
IRAS ID
300554
Contact name
David Sarphie
Contact email
Sponsor organisation
Oxford Medistress Ltd
Duration of Study in the UK
0 years, 3 months, 1 days
Research summary
Oxford MediStress (OMS) has developed the Leukocyte Immuno Test™ (LIT™) to enable clinicians to rapidly assess neutrophil function. Requiring only a single drop of blood test, and testing with the test assay, allows the quantitative assessment of general immunocompetence through measurement of leukocyte (specifically, neutrophil) function, with a measurement in ten minutes.
This promises to enable better prognosis of disease progression in prostate cancer (unpublished data on study by Oxford Medistress) and potentially in other cancers and may, in the future, enable monitoring of neutrophil function during chemotherapy and cancer remission.
The science underpinning this is well understood, having been developed over a number of years with numerous peer-reviewed publications supporting it.
The key objective of this study is to demonstrate the potential of the LIT test measure to provide an a priori assessment of immunocompetence in patients with cancer, and in particular, a primary objective is to evaluate the LIT test measurement as a marker for immunocompetence in patients on chemotherapy for breast cancer. If the hypothesis is proven correct, the key benefit to patient and healthcare would be Immediate availability of blood test results within 10 minutes allowing the treating team a better control on the care plan/pathway. The future aspiration is that with the development of POC test, it would help self-monitoring feasible for the patients although that's not being studied in this project.
REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
21/EE/0146
Date of REC Opinion
2 Jun 2021
REC opinion
Further Information Favourable Opinion